Global COPD Therapeutics Market for Spectacular Growth, Projected to Reach US$ 20,035.5 Million by 2033 at a 5.1% CAGR

COPD Therapeutics Market

Global COPD Therapeutics Market

The global COPD therapeutics market is expected to increase significantly, reaching a valuation of US$ 12,144.1 million in 2023. Based on projections, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% throughout the projected period, reaching US$ 20,035.5 million by 2033.

COPD is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation, primarily caused by smoking, environmental pollutants, and genetic predisposition. With COPD representing a significant public health burden worldwide, effective therapeutics play a crucial role in managing symptoms, reducing exacerbations, and improving patient quality of life.

The anticipated growth in the global COPD therapeutics market can be attributed to several key factors. The increasing prevalence of COPD, particularly in aging populations, coupled with rising tobacco consumption and air pollution levels, is driving the demand for effective treatment options. Additionally, advancements in pharmaceutical research and development, including the introduction of novel therapies and targeted biologics, are expanding the treatment landscape for COPD patients.

Advance Insights With Your Report Sample:

Surgical Procedures for Serious Instances:

Surgery might be advised in COPD instances that are very severe. Treatment options include lung volume reduction surgery, lung transplants, and bullectomies. To stop the disease’s progression and enhance patient outcomes, appropriate therapeutic care is crucial, as evidenced by the high prevalence of COPD.

  • Combination Therapies Are Becoming More PopularThe market for COPD treatments is seeing an increase in patients’ preference for combination treatments over single prescriptions, or monotherapy. LABA-ICS (long-acting beta antagonist and inhaled corticosteroid) and LAMA-ICS (long-acting muscarinic antagonist and inhaled corticosteroid) are two examples of combination therapy that have the following benefits:Enhanced Effectiveness: When it comes to controlling COPD symptoms and raising patients’ quality of life, combination treatments work better than monotherapy.
    Better Patient Outcomes: Combination medications provide a more successful treatment strategy for patients who do not respond well to bronchodilators or corticosteroids alone, which may increase demand for COPD therapeutics.

Key players:

  • Pfizer Inc.
  • Adamis Laboratories Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Merk & Co.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries

Our Methodology Overview:

Key Segments Profiled in the COPD Therapeutics Industry Survey

By Component:

  • COPD Therapeutics Drug Class
  • Bronchodilators
  • Steroids
  • Phosphodiesterase-4 inhibitors
  • Theophylline
  • Antibiotics
  • COPD Therapeutics Delivery Systems
  • Oral
  • Inhalation

By End User:

  • Hospitals
  • Private Clinics
  • Outpatient Departments

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Discover Extensive Market Analysis: Purchase Now to Access:

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries:
LinkedInTwitterBlogs | YouTube

Matched content

Editor’s pick

Express Press Release Distribution